Drugs / RT-01
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05387226 | May → Dec 2022 | T-cell non-Hodgkin lymphoma | The First Affiliated Hospital of Bengbu Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT05205408 | Feb 2022 → Jun 2023 | neoplasm | The First Affiliated Hospital of Bengbu Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT05205421 | Jan 2022 → Jan 2023 | — | The First Affiliated Hospital of Bengbu Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT05228119 | Jan → Oct 2022 | neoplasm | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT05136937 | Nov 2021 → Jun 2022 | cancer | Wuxi People's Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05122572 | Nov 2021 → Jun 2022 | neoplasm | Wuxi People's Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RT-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05122572 ↗ |
| Modality | Other / unclassified | “oncolytic virus injection” NCT05122572 ↗ |
| Route | Intravenous | “RT-01 injection given via Intravenous with or without Intratumoral administration” NCT05122572 ↗ |